Press Releases

Showing 211-245 of 252

First Prev 1 2 3 4 5 6 7 8 Next Last

2011
May
May 10	Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
May 6	Abbott Receives FDA Approval to Expand Use of the RX ACCULINK® Carotid Stent System to Patients at Standard Surgical Risk
May 3	Abbott to Present at Bank of America Merrill Lynch 2011 Health Care Conference

April
April 29	Abbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting
April 29	Abbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with Low Testosterone
April 20	Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter
April 19	Abbott Chairman and CEO Miles D. White Elected to the American Academy of Arts & Sciences
April 15	New Fully Automated Vitamin D Assay Submitted for FDA Clearance
April 12	Abbott Recognized As Company of the Year for Global Halal Initiatives
April 4	Data from Landmark Clinical Trial of Abbott's MitraClip® System Demonstrate Durable Clinical Benefits for Patients with Mitral Regurgitation Two Years After Treatment
April 4	Abbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results
April 4	Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
April 3	Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

March
March 31	Abbott Hosts Conference Call for First-Quarter Earnings
March 31	Abbott Introduces Hepatitis B Sequencing Test in Europe
March 30	Abbott Announces Launch of Catheter-Based MitraClip® System in Australia for Mitral Regurgitation, the Most Common Heart Valve Condition
March 28	Abbott to Present Data on Novel Vascular Technologies and XIENCE V® at ACC 2011
March 28	Abbott Introduces Micro-Implantation Cataract Suite
March 24	Abbott Recognizes Winners of Supplier Excellence Award
March 21	Abbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults
March 14	Abbott Supports Relief Efforts in Japan
March 4	Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology
March 1	Abbott to Present at Barclays Capital 2011 Global Healthcare Conference

February
February 22	Abbott to Present at Cowen and Company 31st Annual Health Care Conference
February 22	Abbott Launches a CE Marked KIF6 Test in Europe
February 18	Abbott Announces Increase in Quarterly Dividend
February 15	Abbott to Present at RBC Capital Markets' Healthcare Conference
February 7	Abbott Introduces Biothreat Assay for PLEX-ID™ System
February 7	Abbott’s Ibis Technology Identified Fatal Disease Organism in Afghanistan

January
January 31	Abbott's TREK® Coronary Balloon System Now Available in the United States and Japan
January 26	Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Ongoing Earnings Outlook for 2011
January 26	FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk
January 25	New Abbott Vitamin D Test Available for Use in the European Union
January 10	Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
January 7	Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti

First Prev 1 2 3 4 5 6 7 8 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.